Advertisement

Search Results

Advertisement



Your search for Debu Tripathy, MD matches 14 pages

Showing 1 - 14


breast cancer

Biomarkers Can Now Help Guide Treatment Selections in Breast Cancer

A growing list of biomarkers is beginning to drive targeted therapy in breast cancer, and clinicians can take advantage of these assays to make treatment selections, Debu Tripathy, MD, Professor of Medicine and Chair of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center,...

breast cancer

How Will ctDNA Assays Aid in Managing Breast Cancer?

CIRCULATING TUMOR DNA (ctDNA) assays are now commercially available for use in lung cancer and melanoma, where they can identify the presence of specific mutations that drive treatment selection. In breast cancer, ctDNA remains more of a research tool, but this is poised to change.  At the 2018...

breast cancer

Ribociclib Doubles Progression-Free Survival in Premenopausal Breast Cancer

PREMENOPAUSAL WOMEN with hormone receptor–positive, HER2-negative advanced breast cancer benefited substantially from the addition of ribociclib (Kisqali) to first-line endocrine therapy plus medical ovarian suppression, according to results from the MONALEESA-7 study.1 At the 2017 San Antonio...

breast cancer

SABCS 2017: MONALEESA-7: Ribociclib Improved Progression-Free Survival for Pre- and Perimenopausal Women With HR-Positive Advanced Breast Cancer

Adding the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor–positive (HR-positive), HER2-negative...

breast cancer

Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast...

breast cancer
supportive care
integrative oncology

Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment

In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...

integrative oncology

Integrative Oncology Modalities Supported by Varying Levels of Evidence, but More Research Needed Overall

Over the past couple of decades, unregulated nonstandard oncology approaches have gained growing popularity among cancer patients. The relatively new field of integrative oncology was established to promote a more holistic and multidisciplinary approach to cancer care and to encourage scientific...

breast cancer

Where Is Adjuvant Bisphosphonate Therapy Now? 

The adjuvant use of bisphosphonates in breast cancer continues to yield seemingly contradictory data despite a sound biologic basis and smaller pilot studies suggesting that dampening bone turnover with bisphosphonates can lessen the bone reservoir of micrometastases.1,2 Early adjuvant trials with...

Expert Point of View: Debu Tripathy, MD

Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage...

Expert Point of View: Debu Tripathy, MD

Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage HER2-positive ...

integrative oncology

Personalized Integrative Cancer Care: Focus of the 11th International Conference of the Society for Integrative Oncology

There were several aspects of the 11th International Conference of the Society for Integrative Oncology (SIO), held October 26-28, 2014, in Houston, that distinguished it from past years. One major change was that this year’s conference was held in collaboration with The University of Texas MD...

breast cancer

Addition of Number of Metastases Improves Prognostic Assessment Tool in Breast Cancer With Brain Metastases

As reported in the Journal of Clinical Oncology by Subbiah et al, the addition of number of brain metastases to the breast graded prognostic assessment (breast-GPA) tool improved the prediction of overall survival in breast cancer patients with brain metastases. The existing breast-GPA includes...

breast cancer
integrative oncology

New Guidelines Issued on Use of Complementary Therapies for Breast Cancer

More than 80% of breast cancer patients in the United States use complementary therapies following a breast cancer diagnosis, but there has been little science-based guidance to inform clinicians and patients about their safety and effectiveness. In newly published clinical practice guidelines...

breast cancer

Dual Targeting of Metastatic Breast Cancer Improves Survival Rates

A new study from the USC Norris Comprehensive Cancer Center showed that targeting both hormone receptors and human epidermal growth factor receptor 2 (HER2) in first-line treatment of patients with metastatic breast cancer significantly increased overall survival times. A team of researchers led...

Advertisement

Advertisement



;
Advertisement